RESUMEN
BACKGROUND: Polypharmacy and its adverse health effects is an emerging public health issue, with increasing prevalence among patients with multiple chronic conditions, such as older adults with diabetes. A healthy lifestyle has been shown to improve both diabetes and polypharmacy incidence. We conducted a cross-sectional study to investigate the association of a healthy lifestyle with polypharmacy and comorbidities in older people with diabetes. METHODS: All out-patients from January 2013 to June 2015 with type II diabetes aged 65 years or more from a Lazio Region reference centre for diabetes were included in the study. Socio-demographic, clinical and lifestyle data were collected from medical records and through face-to-face standardized questionnaires. The comorbidity-polypharmacy score (CPS) was used to characterize the overall patients' frailty, by assessing concurrently the presence of comorbidities and polypharmacy. The cumulative logit model was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs). RESULTS: Adjusted ORs for age, sex, body mass index, physical activity and cognitive status, showed that CPS score was inversely related to weekly consumption of cruciferous vegetables (OR: 0.56, 95% CI: 0.35-0.90; P-trend = 0.015), leafy green vegetables (OR: 0.54, 95% CI: 0.33-0.87; P-trend = 0.013) and daily intake of fruits (OR: 0.63, 95% CI: 0.41-0.97; P-trend = 0.036). Walking outdoors was found inversely related to CPS score (age- and sex-adjusted OR: 0.60, 95% CI: 0.42-0.86). CONCLUSION: Our findings suggest that eating some dietary factors present in the Mediterranean diet and walking outdoors regularly is associated with a lower intensity of medicines need to treat comorbidities among older people with diabetes.
Asunto(s)
Diabetes Mellitus Tipo 2 , Dieta Mediterránea , Anciano , Estudios Transversales , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Diabetes Mellitus Tipo 2/epidemiología , Humanos , Polifarmacia , CaminataRESUMEN
Until now, the basic treatment for food allergy has been to avoid the offending item. This approach is difficult in the case of common foods and in the case where there is a risk of severe reaction after consuming the offending food, even inadvertently. This is the follow-up of a previous study aimed at desensitizing 21 children with immunoglobulin E (IgE)-mediated cow's milk (CM) allergy. This protocol was totally or partially successful in 85% of cases, but failed in the remaining 15%. Our aims were to study the long-term effectiveness and safety of oral CM desensitization, and the prognostic value of Skin Prick Test (SPT) and specific serum CM IgE. The 21 children were called back (one dropped out). The allergic history and other information on CM intake over the last 4-5 yr were recorded. Children underwent SPT, and end-point SPT, with casein and alpha-lactoalbumin. Specific CM IgE was also measured. At follow-up, 14/20 children totally (n = 13, 65%) or partially (n = 1, 5%) tolerated CM. None of the recalled children reported use of emergency care. SPT positivity to casein and/or alpha-lactoalbumin decreased significantly (p < 0.01), and all the negative SPT referred to the tolerant children. Cutaneous sensitivity to both casein and alpha-lactoalbumin (end-point SPT) significantly decreased after the 6-month desensitization period of the previous study (p < 0.001), but did not decrease significantly at follow-up. A significant reduction of serum-specific CM IgE was also observed (p < 0.05). Clinical tolerance induced by oral CM desensitization persists in time. Negativization of SPT and reduction of specific CM IgE could be considered prognostic indicators of CM tolerance. Oral CM desensitization seems to be a promising method to treat CM food allergy. This protocol is time-consuming but offers the advantage that it can be performed at home. This methodology must only be used by trained staff.
Asunto(s)
Alérgenos/inmunología , Desensibilización Inmunológica , Tolerancia Inmunológica/inmunología , Hipersensibilidad a la Leche/inmunología , Leche/inmunología , Alérgenos/efectos adversos , Animales , Niño , Preescolar , Desensibilización Inmunológica/efectos adversos , Epítopos/sangre , Femenino , Estudios de Seguimiento , Humanos , Inmunoglobulina E/sangre , Masculino , Leche/efectos adversos , Hipersensibilidad a la Leche/fisiopatología , Hipersensibilidad a la Leche/terapia , Pronóstico , Titulación a Punto Final de Prueba Cutánea , Factores de TiempoRESUMEN
Atopic dermatitis (AD), a chronic inflammatory skin disease, frequently associated with respiratory allergy, is one of the most common skin disorders observed in children. The prevalence of AD and other allergic diseases is increasing in industrialized countries, representing a major burden on health care cost. AD has been proposed as an "entry point" for subsequent allergic diseases, suggesting the possibility that effective management of AD could prevent the development of respiratory allergy or at least reduce the severity of asthma and allergic rhinitis. AD and asthma share a common genetic and pathogenic basis, and several longitudinal studies provided evidence for the atopic march from AD to allergic rhinitis and asthma. However, because only a few prospective studies starting at children's births and having a sufficiently long follow-up have been developed, little is known about the natural course of AD and the potential succession of atopic phenotypes in childhood. Finally, recent genetic and epidemiological data raised the question whether AD may either develop to asthma or be part of a syndrome consisting of both diseases.
Asunto(s)
Asma , Dermatitis Atópica , Asma/epidemiología , Asma/genética , Asma/fisiopatología , Asma/terapia , Preescolar , Dermatitis Atópica/epidemiología , Dermatitis Atópica/genética , Dermatitis Atópica/fisiopatología , Dermatitis Atópica/terapia , Humanos , Lactante , Fenotipo , Guías de Práctica Clínica como Asunto , Hipersensibilidad Respiratoria/epidemiología , Hipersensibilidad Respiratoria/genética , Hipersensibilidad Respiratoria/fisiopatología , Hipersensibilidad Respiratoria/terapia , Factores de RiesgoRESUMEN
Abbreviated aerosol therapy has been suggested to increase compliance by delivering the same therapeutic dose, but more rapidly than traditional aerosol therapy. A new spacer mouth mask, which is recommended for use in abbreviated aerosol therapy, is now available in Italy. The aim of this study was to compare traditional and abbreviated salbutamol aerosol therapy in 30 asthmatic children using the new spacer mouth mask. Thirty asthmatic children (18 boys and 12 girls; aged 4-13 years) were evaluated during severe asthma attacks (forced expiratory volume at 1 second [FEV(1)] <60% of the predicted value) and randomly allocated to treatment with two different schedules of aerosol therapy. Aerosol therapy was administered to group A in the usual manner, with patients breathing in and out at tidal volume until the nebulizer bowl was empty. Group B received therapy with the new spacer mouth mask used in accordance with manufacturer's instructions, i.e., placing the mask tightly over the mouth and instructing the child to breathe in through the mouth and out through the nose a total of five times at tidal volume, keeping the mouth open. The amount of drug available to patients in group A was approximately 768 microg, whereas 176 microg was available to those in group B. The FEV(1) increased in all patients and there was no difference in the degree of improvement between the groups (p < 0.05). The results indicate equivalent bronchodilatation between abbreviated and traditional aerosol therapy but because abbreviated therapy takes less time, it may improve compliance.
Asunto(s)
Albuterol/administración & dosificación , Asma/tratamiento farmacológico , Broncodilatadores/uso terapéutico , Espaciadores de Inhalación , Administración por Inhalación , Adolescente , Aerosoles , Albuterol/uso terapéutico , Broncodilatadores/administración & dosificación , Niño , Preescolar , Femenino , Humanos , Italia , Masculino , MáscarasRESUMEN
AIM: To evaluate the long-term histological outcome of patients transplanted for HBV-related liver disease and given HBIg prophylaxis indefinitely after LT. METHODS: Forty-two consecutive patients transplanted for hepatitis B were prospectively studied. HBsAg, HBV-DNA and liver function tests were evaluated in the serum 3, 6 and 12 mo after LT and then yearly. LB was obtained 6 and 12 mo after LT and yearly thereafter. Chronic hepatitis (CH) B after LT was classified as minimal, mild, moderate or severe. RESULTS: HBV recurred in 7/42 (16.6%) patients after 6-96 mo of follow-up. A hundred and eighty-seven LB were evaluated. Four of 7 patients with graft reinfection, all with unknown HBV DNA status before LT, developed cirrhosis at 12-36 mo of follow-up. Of the 122 LB obtained from 28 HBsAg+/HCV- recipients with no HBV recurrence after LT, all biopsies were completely normal in only 2 patients (7.1%), minimal/non-specific changes were observed in 18 (64.2%), and at least 1 biopsy showed CH in the remaining 8 (28.5%). Twenty-nine LB obtained from 7 patients transplanted for HBV-HCV cirrhosis and remaining HBsAg- after LT revealed recurrent CH-C. Actuarial survival was similar in patients with HBsAg+ or HBsAg- liver diseases. CONCLUSION: Though protocol biopsies may enable the detection of graft dysfunction at an early stage, the risk of progression and the clinical significance of these findings remains to be determined.